Edition:
United States

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

9.45USD
2:37pm EST
Change (% chg)

$0.35 (+3.85%)
Prev Close
$9.10
Open
$9.10
Day's High
$9.55
Day's Low
$9.10
Volume
22,968
Avg. Vol
147,992
52-wk High
$26.55
52-wk Low
$8.07

Chart for

About

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab... (more)

Overall

Beta: --
Market Cap(Mil.): $527.30
Shares Outstanding(Mil.): 57.95
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 187.16 16.73
EPS (TTM): -- -- --
ROI: -- -0.71 35.60
ROE: -- -3.52 17.23

BRIEF-Coherus Biosciences Says ‍Had Cash And Cash Equivalents Of About $126.9 Million

* COHERUS BIOSCIENCES SAYS ‍HAD CASH AND CASH EQUIVALENTS OF ABOUT $126.9 MILLION AS OF DEC 31 - SEC FILING​ Source text : (http://bit.ly/2qqVZLs) Further company coverage:

Jan 05 2018

BRIEF-Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint

* COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM

Dec 08 2017

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares

Nov 14 2017

BRIEF-Coherus Biosciences Q3 loss per share $1.09

* Coherus Biosciences reports third quarter 2017 operating and financial results

Nov 06 2017

BRIEF-Coherus Biosciences files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​

* Coherus Biosciences Inc - Files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​ - SEC filing Source text: (http://bit.ly/2xYarNR) Further company coverage:

Sep 22 2017

BRIEF-‍Temasek Holdings reports 11.32 pct passive stake in Coherus Biosciences

* ‍Temasek Holdings (private) Ltd​ reports 11.32 pct passive stake in Coherus Biosciences Inc as of Aug 24 - sec filing Source text - http://bit.ly/2esXsfi Further company coverage:

Aug 31 2017

BRIEF-Coherus Biosciences announces positive topline results for study for Humira biosimilar vs European marketed Humira in healthy subjects

* Coherus Biosciences announces positive topline results for clinical pharmacokinetic bioequivalence study for CHS-1420 (Humira® biosimilar candidate) versus European marketed Humira in healthy subjects

Aug 28 2017

Competitors

  Price Chg
Amgen, Inc. (AMGN.OQ) $185.00 +2.02
Pfizer Inc. (PFE.N) $36.48 +0.47
Mylan NV (MYL.OQ) $41.81 +0.47
Teva Pharmaceutical Industries Limited (TEVA.TA) 6,959.00 -167.00
LG Chem Ltd (051910.KS) ₩374,500.00 -2,000.00
LG Chem Ltd (051915.KS) ₩218,500.00 -5,500.00
AbbVie Inc (ABBV.N) $120.39 +2.41
Momenta Pharmaceuticals, Inc. (MNTA.OQ) $16.70 +0.75
FUJIFILM Holdings Corp (4901.T) ¥4,358 -7.00

Earnings vs. Estimates